60 Degrees Pharmaceuticals, Inc. (SXTP)
0.9193
-0.01
(-1.16%)
USD |
NASDAQ |
Sep 04, 16:00
0.9312
+0.01
(+1.29%)
After-Hours: 20:00
60 Degrees Pharmaceuticals Research and Development Expense (Quarterly) : 0.5987M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.5987M |
| March 31, 2026 | 0.2815M |
| December 31, 2025 | 0.6389M |
| September 30, 2025 | 0.8098M |
| June 30, 2025 | 0.2319M |
| March 31, 2025 | 0.4076M |
| December 31, 2024 | 0.614M |
| September 30, 2024 | 0.9401M |
| June 30, 2024 | 3.095M |
| Date | Value |
|---|---|
| March 31, 2024 | 0.3372M |
| December 31, 2023 | 0.1002M |
| September 30, 2023 | 0.2637M |
| June 30, 2023 | 0.2039M |
| March 31, 2023 | 0.124M |
| September 30, 2022 | 0.0277M |
| March 31, 2022 | 0.0631M |
| December 31, 2021 | 0.4337M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Harrow, Inc. | 8.072M |
| ANI Pharmaceuticals, Inc. | 14.75M |
| Corcept Therapeutics, Inc. | 53.89M |
| Veru, Inc. | 4.353M |
| Johnson & Johnson | 3.603B |